Century Therapeutics Q2 2026: Net loss $34.6M, cash $197.2M, CNTY-813 IND on track for 4Q26

Century Therapeutics, Inc.

2026-Q2 EPS reported -$0.28

Q2 2026 net loss $34.6M vs $32.5M in Q2 2025; R&D $19.6M (down from $26.9M), G&A $5.8M (down from $7.8M).
Cash, equivalents and investments $197.2M at June 30, 2026, up from $117.1M at Dec 31, 2025; runway into 1Q 2029.
FDA pre-IND alignment for CNTY-813; IND submission on track for 4Q 2026, initial data expected 2H 2027.
CNTY-308, CD19-targeted CAR-iT therapy with Allo-Evasion 5.0, remains on track to enter clinic in 2026.
Preclinical data at ADA 2026 showed durable glucose control >8 months; oral presentations at EASD and CRC 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.